Serving the Society Since 1986
Advanced Search
Volume 28 Issue 1
February 2013
    Citation: Chunchen Wu, Hui Shi, Mengji Lu, Yang Xu, Xinwen Chen. A Case of Hepatitis B Reactivation in an Anti-HBs Positive, Anti-HBc Positive non-Hodgkins Lymphoma Patient .VIROLOGICA SINICA, 2013, 28(1) : 49-52.  http://dx.doi.org/10.1007/s12250-013-3285-x
    shu

    A Case of Hepatitis B Reactivation in an Anti-HBs Positive, Anti-HBc Positive non-Hodgkins Lymphoma Patient

    cstr: 32224.14.s12250-013-3285-x
    • 1.

      State Key Lab of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China

    • 2.

      Department of Microbiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    • 3.

      Institute of Virology, University Hospital of Essen, Essen D45122, Germany

    • Corresponding author: Chunchen Wu, wucc@wh.iov.cn
      Yang Xu, xuyangs@gmail.com
    • Received Date: 11 September 2012
      Accepted Date: 14 January 2013
      Available online: 01 February 2013

      Fund Project: the Fundamental Research Funds for the Central Universities HUST: 2012QN140the National Basic Research Priorities Program of China 2011CB106303National Natural Science Foundation of China 31200699

    • 加载中

      1. Alexopoulou A, Dourakis S P, Pandelidaki H, Archimandritis A J and Karayiannis P. 2006. Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol, 78: 1043-1046.
          doi: 10.1002/(ISSN)1096-9071

      2. Awerkiew S, Daumer M, Reiser M, Wend U C, Pfister H, Kaiser R, Willems W R and Gerlich W H. 2007. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol, 38: 83-86.
          doi: 10.1016/j.jcv.2006.10.006

      3. Carman W F, Korula J, Wallace L, MacPhee R, Mimms L and Decker R. 1995. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet, 345: 1406-1407.
          doi: 10.1016/S0140-6736(95)92599-6

      4. Dahlen D D, Broudy V C and Drachman J G. 2003. Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs. Blood, 102: 102-108.
          doi: 10.1182/blood-2002-11-3468

      5. Ferreira R, Carvalheiro J, Torres J, Fernandes A, Giestas S, Mendes S, Agostinho C and Campos M J. 2012. Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: A case report and literature review. Saudi J Gastroenterol, 18: 277-281.
          doi: 10.4103/1319-3767.98436

      6. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N and Sueoka E. 2009. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol, 20: 2013-2017.
          doi: 10.1093/annonc/mdp230

      7. Iannitto E, Minardi V, Calvaruso G, Mule A, Ammatuna E, Di Trapani R, Ferraro D, Abbadessa V, Craxi A and Di Stefano R. 2005. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol, 74: 254-258.
          doi: 10.1111/ejh.2005.74.issue-3

      8. Lee I C, Huang Y H, Chu C J, Lee P C, Lin H C and Lee S D. 2010. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc, 73: 156-160.
          doi: 10.1016/S1726-4901(10)70031-9

      9. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M and Takeuchi M. 2010. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer, 116: 4769-4776.
          doi: 10.1002/cncr.v116:20

      10. Mele A, Tancredi F, Romano L, Giuseppone A, Colucci M, Sangiuolo A, Lecce R, Adamo B, Tosti M E, Taliani G and Zanetti A R. 2001. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis, 184: 905-908.
          doi: 10.1086/jid.2001.184.issue-7

      11. Moerman B, Moons V, Sommer H, Schmitt Y and Stetter M. 2004. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab, 50: 159-162.

      12. Nainan O V, Khristova M L, Byun K, Xia G, Taylor P E, Stevens C E and Margolis H S. 2002. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol, 68: 319-327.
          doi: 10.1002/(ISSN)1096-9071

      13. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M and Asaka M. 2005. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation, 79: 616-619.
          doi: 10.1097/01.TP.0000151661.52601.FB

      14. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde K H, Neuhaus P and Gerken G. 1998. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology, 27: 254-263.
          doi: 10.1002/hep.v27:1

      15. Sarrecchia C, Cappelli A and Aiello P. 2005. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother, 11: 189-191.
          doi: 10.1007/s10156-005-0385-Z

      16. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, Matsuura B, Kajiwara T, Masumoto T, Horiike N and Onji M. 2006. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med, 45: 721-724.
          doi: 10.2169/internalmedicine.45.1590

      17. Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, Kanamori H, Tanaka J, Asaka M, Imamura M and Masauzi N. 2004. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma, 45: 627-629.
          doi: 10.1080/1042819031000151923

      18. Westhoff T H, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer J H, Zidek W, Gerlich W H and Thiel E. 2003. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood, 102: 1930.
          doi: 10.1182/blood-2003-05-1403

      19. Wu C, Shi H, Wang Y, Lu M, Xu Y and Chen X. 2012. A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy. Virol Sin, 27: 368-371.
          doi: 10.1007/s12250-012-3284-3

      20. Yamagata M, Murohisa T, Tsuchida K, Okamoto Y, Tsunoda S, Nakamura M, Kusano K, Majima Y, Kuniyoshi T, Iijima M, Sugaya H and Hiraishi H. 2007. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma, 48: 431-433.
          doi: 10.1080/10428190601059704

      21. Yeo W, Chan T C, Leung N W, Lam W Y, Mo F K, Chu M T, Chan H L, Hui E P, Lei K I, Mok T S and Chan P K. 2009. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol, 27: 605-611.
          doi: 10.1200/JCO.2008.18.0182

      22. Zhang J M, Xu Y, Wang X Y, Yin Y K, Wu X H, Weng X H and Lu M. 2007. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis, 44: 1161-1169.
          doi: 10.1086/513200

    • 加载中

    Figures(1)

    PDF

    Article Metrics

    Article views(4732) PDF downloads(14) Cited by()

    Related
    Proportional views

      A Case of Hepatitis B Reactivation in an Anti-HBs Positive, Anti-HBc Positive non-Hodgkins Lymphoma Patient

        Corresponding author: Chunchen Wu, wucc@wh.iov.cn
        Corresponding author: Yang Xu, xuyangs@gmail.com
      • 1. State Key Lab of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
      • 2. Department of Microbiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
      • 3. Institute of Virology, University Hospital of Essen, Essen D45122, Germany
      • Received Date: 11 September 2012
      • Accepted Date: 14 January 2013
      Fund Project:  the Fundamental Research Funds for the Central Universities HUST: 2012QN140the National Basic Research Priorities Program of China 2011CB106303National Natural Science Foundation of China 31200699

      Abstract: 

        HTML

      Dear Editor,